Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
Status unconfirmed · Phase 2
Conditions studied: Triple-negative Breast Cancer
In brief
The standard treatment for women with stage I, II, and III triple-negative breast cancer (TNBC) includes chemotherapy and surgery, with or without radiation therapy. However, because TNBC is usually more aggressive, harder to treat, and more likely to come back, it is associated with poor long-term outcomes (survival rates) when compared to other types of breast cancer. Therefore, researchers are studying how new drugs and treatment combinations can improve the outcome of patients with TNBC. This study will test effectiveness of immune therapy (Pembrolizumab is an "immunotherapy" that is expected to work with the body's immune system to help fight cancer) in combination with chemotherapy given before surgery.
Key facts
- Study ID
- NCT03639948
- Run by
- University of Kansas Medical Center
- People needed
- 120
- Starts
- 2018-09-04
- Expected to finish
- 2024-11-01
- Last updated by the study team
- 2024-04-11
Who can join
Age: 18 and older, up to 70. Sex: female. Healthy volunteers: not accepted.
Where it is running
- The University of Kansas Cancer Center (KUCC) — Fairway, Kansas, United States
- The University of Kansas Cancer Center, West Clinic — Kansas City, Kansas, United States
- The University of Kansas Cancer Center, Westwood Campus — Kansas City, Kansas, United States
- University of Kansas Cancer Center — Kansas City, Kansas, United States
- The University of Kansas Cancer Center, Overland Park Clinic — Overland Park, Kansas, United States
- The University of Kansas Cancer Center, North Clinic — Kansas City, Missouri, United States
- The University of Kansas Cancer Center, Lee's Summit Clinic — Lee's Summit, Missouri, United States
- The University of Kansas Medical Center — North Kansas City, Missouri, United States
- Texas Oncology- Baylor — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.